Derazantinib hydrochloride salt form · hydrochloride · Parent ARQ-087 · Synonyms: ARQ 087 2HCl | AQ 14741087 | Derazantinib dihydrochloride

Derazantinib dihydrochloride is an ATP competitive and orally activeFGFR inhibitor.

For research use only. Not for human or veterinary use.

Target EGFR

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Derazantinib hydrochloride structure

CAS No.: 1821329-75-2

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
10 mg	USD 450.00	BP-01858A-10mg	In stock	Get quote
25 mg	USD 585.00	BP-01858A-25mg	In stock	Get quote
50 mg	USD 825.00	BP-01858A-50mg	In stock	Get quote
100 mg	USD 1,185.00	BP-01858A-100mg	In stock	Get quote
250 mg	USD 1,685.00	BP-01858A-250mg	In stock	Get quote
500 mg	Inquire	BP-01858A-500mg	Inquire	Inquire
1 g	Inquire	BP-01858A-1g	Inquire	Inquire

Custom Size Bulk Inquiry

Related forms

BP-01858 — ARQ-087

Description

Derazantinib (ARQ-087) dihydrochloride is an ATP competitive and orally activeFGFR inhibitor (IC50s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3). Derazantinib dihydrochloride inhibits FGFR phosphorylation. Derazantinib dihydrochloride inhibits tumor growth in multiple xenograft models.

Identifiers

SMILES: FC1=C([C@H]2C=3C(C=4C(C2)=CN=C(NC5=CC(CCNCCOC)=CC=C5)N4)=CC=CC3)C=CC=C1.Cl
InChIKey: FJQGYPSAODOLEW-UFTMZEDQSA-N

Specifications

MW (average): 505.0260
Formula: C₂₉H₃₀ClFN₄O
CAS No.: 1821329-75-2
Physical state: Solid
Color: white to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Hall TG, et al. Preclinical Activity of ARQ-087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594.

[2]. Balek L, et al. ARQ-087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3. Bone. 2017 Dec;105:57-66.

Same target

Search EGFR

Same research area

Search Cancer